Sugi Predict

Sugi Predict / Compounds / SCHEMBL10733

SCHEMBL10733

SCHEMBL10733

COC(=O)CCc1cccc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIPG Q9Y5X9 4/20 0.58
▸ LPL P06858 3/20 0.58
▸ SIRT2 Q8IXJ6 1/20 0.44
▸ HIF1A Q16665 2/20 0.39
▸ PTPN1 P18031 2/20 0.38
▸ DGAT1 O75907 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ GSK3A P49840 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ BRD4 O60885 1/20 0.38
▸ PDE4D Q08499 1/20 0.37
▸ CYP4F2 P78329 2/20 0.37
▸ CYP4A11 Q02928 2/20 0.37
▸ IDO1 P14902 1/20 0.37
▸ AKR1C3 P42330 1/20 0.37
▸ AKR1C2 P52895 1/20 0.37
▸ CA12 O43570 1/20 0.36
▸ CA7 P43166 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ CA14 Q9ULX7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2823269 0.87 LIPG (0.59) LIPGLPLHIF1ACYP4F2CYP4A11
SCHEMBL137029 0.86 LIPG (0.53) LIPGLPLHIF1ADGAT1GSK3A
SCHEMBL28051322 0.86 LIPG (0.45) LIPGLPLHIF1ADGAT1GSK3A
SCHEMBL1704489 0.86 LIPG (0.54) LIPGLPLHIF1ADGAT1AKR1C3
SCHEMBL901322 0.85 LIPG (0.74) LIPGLPL
SCHEMBL19510783 0.85 LIPG (0.48) LIPGLPLHIF1ADGAT1CA9
SCHEMBL30462910 0.85 LIPG (0.48) LIPGLPLHIF1ADGAT1CA9
SCHEMBL1525152 0.83 LIPG (0.58) LIPGLPLHIF1ADGAT1CA12
SCHEMBL14584 0.83 LIPG (0.40) LIPGLPLSIRT2PTPN1CNR2
SCHEMBL12802770 0.81 LIPG (0.54) LIPGLPLHIF1ACYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof LG CHEM, LTD. (KR) 2026-05-19 — — US disclosed
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
EP-4313967-B1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2025-11-12 — — EP disclosed
US-12410160-B2 KHK inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
EP-4071147-B1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF LG CHEMICAL LTD (KR) 2025-03-26 — — EP disclosed
US-20240424111-A1 Degrader Compounds and Uses Thereof CALICO LIFE SCIENCES LLC (US) 2024-12-26 — — US disclosed
EP-4313967-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-07 — — EP disclosed
CN-117120429-A KHK inhibitor 吉利德科学公司 2023-11-24 — — CN disclosed
EP-2970176-B1 MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO CORTEVA AGRISCIENCE LLC (US) 2023-10-25 — — EP disclosed
US-7935688-B2 Vitamin D-like compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-05-03 — — US disclosed
US-7935688-B2 Vitamin D-like compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-05-03 — — US disclosed
WO-2011041694-A2 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-07 — — WO disclosed
US-20110060146-A1 VITAMIN-D-LIKE COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-03-10 — — US disclosed
US-20110060146-A1 VITAMIN-D-LIKE COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-03-10 — — US disclosed
US-20110060146-A1 VITAMIN-D-LIKE COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-03-10 — — US disclosed
US-20090137609-A1 VITAMIN D-LIKE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-05-28 — — US disclosed
US-20090137609-A1 VITAMIN D-LIKE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-05-28 — — US disclosed
US-20090137609-A1 VITAMIN D-LIKE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-05-28 — — US disclosed
EP-1894911-A1 VITAMIN D-LIKE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-03-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137609-A1 VITAMIN D-LIKE COMPOUND VDR, CYP24A1, CYP2R1 LIPG 2803/4885LPL 2139/4885SIRT2 1167/4885
US-20240424111-A1 Degrader Compounds and Uses Thereof PTPN1, PTPN2, PTPN5 LIPG 395/4885LPL 266/4885SIRT2 3834/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 LIPG 249/4885LPL 178/4885SIRT2 1009/4885
US-12410160-B2 KHK inhibitors KHK, KHDRBS1, NADK LIPG 2261/4885LPL 3327/4885SIRT2 834/4885
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof DGAT2, DGAT1, SOAT2 LIPG 118/4885LPL 66/4885SIRT2 1731/4885
US-20110060146-A1 VITAMIN-D-LIKE COMPOUNDS VDR, CYP24A1, CYP2R1 LIPG 2624/4885LPL 1969/4885SIRT2 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.